- Conditions
- Coronary Heart Disease, Graft Occlusion, Vascular
- Interventions
- Placebo, RO4905417
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 27
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Los Angeles, California + 21 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 1,029
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Plague
- Interventions
- Alhydrogel, rF1 and rV protein antigens
- Biological
- Lead sponsor
- PharmAthene UK Limited
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 9
- States / cities
- Huntsville, Alabama • Washington D.C., District of Columbia • Gainesville, Florida + 6 more
- Conditions
- Retinitis Pigmentosa
- Interventions
- BS01
- Drug
- Lead sponsor
- Bionic Sight LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 1
- States / cities
- Teaneck, New Jersey
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Interventions
- recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acquired Bleeding Disorder, Intracerebral Haemorrhage
- Interventions
- eptacog alfa (activated)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 829 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
- Conditions
- Paramyxoviridae Infections, Virus Diseases
- Interventions
- rHPIV3cp45, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 36 Months
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Diarrhea
- Interventions
- rFla-MBP
- Biological
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 40 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- X-Linked Myotubular Myopathy
- Interventions
- ASP2957, Methylprednisolone, Prednisolone, Sirolimus
- Genetic · Drug
- Lead sponsor
- Astellas Gene Therapies
- Industry
- Eligibility
- Up to 36 Months · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Portland, Oregon + 1 more
- Conditions
- Ischemia Reperfusion Injury
- Interventions
- recombinant P-selectin glycoprotein ligand Ig fusion protein, Viaspan® and saline
- Drug
- Lead sponsor
- Y's Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Primary Immunodeficiency Diseases (PID)
- Interventions
- Immune Globulin Infusion (Human), 10%, Recombinant human hyaluronidase
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 10
- States / cities
- Irvine, California • Thornton, Colorado • North Palm Beach, Florida + 7 more
- Conditions
- SARS-CoV-2 Infection
- Interventions
- Intramuscular injection, Intramuscular vaccine
- Drug · Biological
- Lead sponsor
- Medicago
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30,918 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Tempe, Arizona • Canoga Park, California + 39 more
- Conditions
- Thyroid Cancer
- Interventions
- Euthyroid Group
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Houston, Texas
- Conditions
- Parainfluenza, Virus Diseases
- Interventions
- rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 49 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Von Willebrand Disease
- Interventions
- Recombinant von Willebrand factor (rVWF), Placebo, Recombinant factor VIIII (rFVIII)
- Biological · Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 10
- States / cities
- Sacramento, California • Miami, Florida • Peoria, Illinois + 7 more
- Conditions
- Malignant Glioma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Glioblastoma, Gliosarcoma, Atypical Teratoid/Rhabdoid Tumor of Brain, Medulloblastoma, Ependymoma, Pleomorphic Xanthoastrocytoma of Brain, Embryonal Tumor of Brain
- Interventions
- Polio/Rhinovirus Recombinant (PVSRIPO)
- Biological
- Lead sponsor
- Istari Oncology, Inc.
- Industry
- Eligibility
- 12 Years to 21 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Ocular Graft vs Host Disease, Dry Eye
- Interventions
- rhDNase I, Vehicle
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Localized Prostate Cancer
- Interventions
- Ad5-SGE-REIC/Dkk3
- Drug
- Lead sponsor
- Momotaro-Gene Inc.
- Industry
- Eligibility
- 50 Years to 80 Years · Male only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 3
- States / cities
- San Diego, California • Boston, Massachusetts • Houston, Texas
- Conditions
- HIV Infections
- Interventions
- VRC-HIVADV027-00-VP, VRC-HIVADV038-00-VP, VRC-HIVDNA044-00-VP
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2013
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • San Francisco, California • New York, New York + 3 more
- Conditions
- RSV Infection
- Interventions
- RSV 6120/∆NS2/1030s, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 60 Months
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Dehydration
- Interventions
- Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
- Drug
- Lead sponsor
- Baxter Healthcare Corporation
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- TF2/IMP288
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Spinal Surgery, Vascular Surgery
- Interventions
- rThrombin
- Biological
- Lead sponsor
- ZymoGenetics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Kidney Transplant Recipient Response to Shingrix Vaccine, Kidney Failure, Kidney Failure, Chronic, Kidney Transplantation, Herpes Zoster (HZ)
- Interventions
- Shingrix
- Biological
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 1 more
- Conditions
- HIV Infections
- Interventions
- rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)]), rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349])
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 24 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2009
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 4 more